IGF-1 and related compounds in pregnancy
US5420111A · kind A · utility
7Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 1993 |
| Grant date | May 30, 1995 |
| Priority date | — |
| Expiry date | Feb 10, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fetal growth is promoted and fetal growth retardation is reduced in mammals by increasing in a maternal host during pregnancy the active concentration of IGF-1 and /or IGF-2 and/or analogues thereof. The active concentration of IGF-1 and/or IGF-2 and/or analogues thereof may be increased either by directly administering to the maternal host IGF-1 and/or IGF-2 and/or analogs thereof or by administering another compound which, upon being so administered, causes an increase in the active concentration of IGF-1 and/or IGF-2 and/or analogues thereof in the maternal host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.